Correlation of Antioxidants Enzymes Activity with Fasting Blood Glucose in Diabetic Patients in Sokoto, Nigeria

2018 ◽  
Vol 25 (12) ◽  
pp. 1-6 ◽  
Author(s):  
A Ngaski
Keyword(s):  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Diabetic Patients ◽  
Enzymes Activity ◽  
Antioxidants Enzymes

scholarly journals Daily Fasting Blood Glucose Rhythm in Male Mice: A Role of the Circadian Clock in the Liver

Endocrinology ◽  
2015 ◽  
Vol 157 (2) ◽  
pp. 463-469 ◽  
Author(s):  
Hitoshi Ando ◽  
Kentaro Ushijima ◽  
Shigeki Shimba ◽  
Akio Fujimura
Keyword(s):  
Blood Glucose ◽  
Circadian Clock ◽  
Mrna Expression ◽  
Hepatic Glucose Production ◽  
Critical Role ◽  
Fasting Blood Glucose ◽  
Glucose Production ◽  
Diabetic Patients ◽  
Dark Phase ◽  
Dawn Phenomenon

Abstract Fasting blood glucose (FBG) and hepatic glucose production are regulated according to a circadian rhythm. An early morning increase in FBG levels, which is pronounced among diabetic patients, is known as the dawn phenomenon. Although the intracellular circadian clock generates various molecular rhythms, whether the hepatic clock is involved in FBG rhythm remains unclear. To address this issue, we investigated the effects of phase shift and disruption of the hepatic clock on the FBG rhythm. In both C57BL/6J and diabetic ob/ob mice, FBG exhibited significant daily rhythms with a peak at the beginning of the dark phase. Light-phase restricted feeding altered the phase of FBG rhythm mildly in C57BL/6J mice and greatly in ob/ob mice, in concert with the phase shifts of mRNA expression rhythms of the clock and glucose production–related genes in the liver. Moreover, the rhythmicity of FBG and Glut2 expression was not detected in liver-specific Bmal1-deficient mice. Furthermore, treatment with octreotide suppressed the plasma growth hormone concentration but did not affect the hepatic mRNA expression of the clock genes or the rise in FBG during the latter half of the resting phase in C57BL/6J mice. These results suggest that the hepatic circadian clock plays a critical role in regulating the daily FBG rhythm, including the dawn phenomenon.

scholarly journals The Effect of A New Mixture of Sugar and Sugar-Alcohol (Lacritose) on Blood Glucose and Lipids and the Possible Adverse Reactions in Patients with Type 2 Diabetes: A Triple-Blind Randomized Clinical Trial

2021 ◽  
Author(s):  
Masoud Rahmanian ◽  
Zohreh Mozafari ◽  
Danial Chaleshi ◽  
Marzieh Shukohifar ◽  
Saeedeh Jam-Ashkezari
Keyword(s):  
Clinical Trial ◽  
Blood Glucose ◽  
Randomized Clinical Trial ◽  
Fasting Blood Glucose ◽  
Resistance Index ◽  
Primary Data ◽  
Control Group ◽  
Diabetic Patients ◽  
Diabetes Research

Background: A new sweetener with the commercial name of Lacritose has been recently produced, which is a combination of four simple sugars (lactose, fructose, sucrose, erythritol), with specific ingredients and percentages. This study aimed to assess glycemic response and short term gastrointestinal reactions in type 2 diabetic patients. Methods: In this triple-blind randomized clinical trial, 30 diabetic patients referred to Yazd Diabetes Research Center in 2018 were included. After collecting the primary data, they were assigned into three groups, including sucrose consumers as the control group, sucrose-lactose, and lacritose as the groups of consumers group. They were followed for two weeks, and fasting blood glucose (FBG), 2-hour postprandial test (2HPP), fructose amine, SGOT, SGPT, urea, creatinine, and insulin resistance index (HOMA-IR) were assessed. Results: In lacritose consumers, significant reductions were seen in FBG and 2HPP (P < 0.001 and P = 0.05, respectively), although changes among the groups were not significant. In sucrose-lacritose consumers, FBG and cholesterol levels decreased (P = 0.04 and P = 0.03, respectively). In sucrose consumers, no reduction was seen. HOMA-IR did not significantly decrease, but intergroup changes were obvious. Conclusion: The lacritose effects on FBG and 2HPP were significantly evident, but the other metabolic indices did not show any significant change.

scholarly journals Treatment outcome and its predictors among diabetic patients attending at selected hospitals of southern ethiopia.

2021 ◽  
Author(s):  
Bereket Beyene ◽  
Dawit Hoyiso ◽  
Kinfe Woldu
Keyword(s):  
Treatment Outcome ◽  
Blood Glucose ◽  
Health Care Expenditure ◽  
Fasting Blood Glucose ◽  
World Health ◽  
Outcome Variable ◽  
Southern Ethiopia ◽  
Diabetic Patients ◽  
Source Population ◽  
Good Treatment Outcome

Abstract Background: Diabetes is one of the largest health emergencies of the 21st century. The World Health Organization (WHO) estimates that globally, hyperglycaemia is the third highest risk factor for premature mortality, after high blood pressure and tobacco use. It is an important cause of blindness, kidney failure, lower limb amputation and other long-term consequences that impact significantly on quality of life. It result peoples in a disease, death and increase a health care expenditure.Objectives: To determine treatment outcome of Diabetes mellitus and its predictors among patients attending diabetes treatments at selected hospitals of southern Ethiopia, 2021.Methods: All diabetic patients who attended selected hospitals of southern Ethiopia were a source population. Institution based cross-sectional study design was conducted at selected hospitals of southern Ethiopia. Patient’s data was collected using pretested questionnaire. After cleaning and checking for errors, the data was entered in to Epi-data to minimize error then exported to SPSS for analysis. Descriptive findings were presented by tables and charts. The outcome variable was analyzed by using logistic regression model to identify predictors after assumptions of regression analysis had checked. All the independent variables with p<0.25 was used as a candidate for multivariate analysis. Then the level of significance will be set at p<0.05 and AOR with 95% CL was done as the final model.Result: From the total sample; 277 (65.6%) were found to be good treatment outcome. The number of medication taken AOR 95%CI; 0.924 (0.869, 0.983), presence of complication AOR 95%CI; 0.425 (0.217, .832), increased fasting blood glucose AOR 95%CI; 0.080 (0.034, 0.188) were found to be independent predictors. Since the magnitude of treatment outcome found to be low, provision of health information about the adhering to prescribed medication and monitoring fasting blood glucose level will bring good clinical outcome.

scholarly journals Alterations of liver enzymes in T2DM: a case control study

2018 ◽  
Vol 5 (6) ◽  
pp. 1521
Author(s):  
Chandrashekhar G. S.
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Case Control Study ◽  
Liver Enzymes ◽  
Fasting Blood Glucose ◽  
Case Control ◽  
Diabetic Patients ◽  
Histopathological Analysis ◽  
Control Study

Background: Liver plays an important role in regulation of blood glucose in fed state as well as in fasting. Diabetes mellitus can result as a consequence of liver disorder and vice versa. Objective of the present study is to compare the liver enzymes in type 2 diabetic patients as compared to non-diabetic patients.Methods: A case- control study was conducted in Clinical Biochemistry Laboratory, Adarsha Super speciality Hospital, Udupi from April 2018 to August 2018. The data of 174 diabetic patients and 118 healthy people as controls was collected. Fasting blood glucose, aspartate aminotransferase (AST), alanine amino transferase (ALT) and alkaline phosphatase (ALP) were estimated in the study subjects.Results: It was found that AST levels (47.55±4.69U/L) in diabetics extremely significantly high as compared to controls (33.51±2.33U/L). ALT levels were insignificantly high in diabetics compared to controls. ALP was significantly elevated (p=0.0002) in diabetics. Correlation study showed a weak positive correlation between AST, ALT and blood glucose. Odds ratio showed a higher risk of liver enzyme elevation in diabetics. Risk of elevation of AST was found to be 1.65 times high and ALT was 1.25 times high in diabetics compared to non-diabetics.Conclusions: Diabetics had high liver enzymes as compared to non-diabetics. An association was found between type 2 diabetes mellitus and liver enzymes. For better characterization of cause and effect, further studies need to be done on alterations in liver function tests along with the histopathological analysis of liver biopsy samples.

scholarly journals Correlation between glycated hemoglobin HbA1c and serum lipid profile in patients with type 2 diabetes

2021 ◽  
pp. 14-18
Author(s):  
Asmaa Alboueishi
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Blood Glucose ◽  
Serum Lipid ◽  
Clinical Laboratory ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Diabetic Patients

Background: Hyperlipidemia is a common risk factor for diabetes that leads to cardiovascular disease, one of the causes of death of diabetic patients. Theaimof this study was to investigate the association between HbA1c levels and serum lipids in Libyan patients withtype 2 diabetes. Material and methods: The study was conducted in 2019 on 325 patients (174 males, 151 females) with type 2 diabetes referred to a private clinical laboratory in Tripoli, Libya. Blood samples were collected for measurement of HbA1c, fasting blood glucose and serum lipid concentrations. Diabetes was defined according to the American Diabetes Association criteria.The data were analyzed using an independent t-test and Pearson’scorrelation test.Results: The ages of the patients ranged from 40 to 83 years, with a mean of 51.52 ± 14.32 years SD. No significant correlation between HbA1c and age was noted (r=0.011, p=0.063). There was a significant positive correlation betweenHbA1c level and fasting blood glucose (r =0.641, p=0.000), low-density lipoprotein (r = 0.240, p = 0.000), total cholesterol (r = 0.223, p = 0.000) and triglycerides(r=0.140,p 0.067). The correlation between HbA1c and high-density lipoprotein-C was negative but not significant (r= -0.088, p = 0.123). Conclusion: HbA1c could be used as a predictor of dyslipidemia and thus it may serve as anindicator of the development of cardiovascular disease in patients with type-2 diabetes mellitus.

scholarly journals Utilizing Technology-Enabled Intervention to Improve Blood Glucose Self-Management Outcome in Type 2 Diabetic Patients Initiated on Insulin Therapy: A Retrospective Real-World Study

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jian Lin ◽  
Xia Li ◽  
Shan Jiang ◽  
Xiao Ma ◽  
Yuxin Yang ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glycemic Control ◽  
Insulin Therapy ◽  
Fasting Blood Glucose ◽  
Blood Glucose Control ◽  
Diabetic Patients ◽  
Premixed Insulin ◽  
Type 2 Diabetic Patients ◽  
Self Monitoring

Background. The aim of this study was to assess the benefits of a mobile-enabled app through Lilly Connected Care Program (LCCP) in achieving blood glucose control and adhering to self-monitoring of blood glucose in patients with type 2 diabetes mellitus (T2DM). Methods. This retrospective study included T2DM patients who were initiated on insulin therapy (mostly premixed insulin) after failure to respond to oral antidiabetic drugs. Patients were provided with glucometers enabled with synchronous data transmission to healthcare providers and family members. The primary objective was to assess the benefits of LCCP based on changes in fasting blood glucose (FBG) and postprandial glucose (PPG) levels from baseline to 12 weeks. Paired t-test was used to assess the change in blood glucose (BG) from baseline to week 12. Results. In total, 14,085 T2DM patients were recruited. Compared with baseline, significant reductions in FBG and PPG were evident at week 12 (FBG: -0.39 mmol/L; PPG: −0.79 mmol/L; both P < 0.001 ). Furthermore, at week 12, the proportion of patients attaining a target glucose level of FBG <7.0 mmol/L and PPG <10.0 mmol/L was 25.37% and 59.68%, respectively, with a statistically significant increase compared with that at baseline (6.74% and 45.59%, respectively, both P < 0.001 ). The frequent monitoring of patients could gain a higher target achievement of FBG (28.1% vs 24.2%) and PPG (64.4% vs 55.1%) than the occasional monitoring patients. Additionally, the incidence of hypoglycemia gradually decreased and was significantly lower than the baseline level. Conclusions. In T2DM patients with poor glycemic control, the application of mobile enabled intervention (LCCP) along with insulin significantly reduced the hypoglycemia while improving glycemic control during period of naïve initiating insulin therapy. Additionally, the high frequency of BG self-monitoring was associated with better glycemic control.

The Effect of Biochanin A as PPAR γ agonist on LDL Particles Diameter and Type 2 Diabetic Dyslipidemia

2019 ◽  
Author(s):  
Darya Ghadimi ◽  
Mohammad Taghi Taghi Goodarzi ◽  
Mahdi Bahmani ◽  
Zohre Khajehahmadi
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Male Rats ◽  
Biochanin A ◽  
Diabetic Patients ◽  
Low Density ◽  
Diabetic Dyslipidemia ◽  
Ldl Particles

Background and Aims: Small dense  low-density lipoproteins (sd-LDL) particles are smaller and heavier than typical LDL ones. They can penetrate into the endothelium of coronary arteries more easily because of their small size. Diabetes mellitus is accompanied by dyslipidemia such as increasing concentration of plasma very low density lipoprotein and sd-LDL. Peroxisome proliferator activated receptor γ (PPARγ ) can decrease the level of sd-LDL in plasma. Biochanin A (BCA), a natural compound, is a PPARγ agonist. The present study was designed to investigate the effect of BCA on sd-LDL-Clolesterol level in diabetic animals. Materials and Methods: Adult male rats (Wistar strain) were used as the animal models in this study. Animals were made diabetic by single intraperitoneal injection of Streptozotocin- Nicotinamide and then treated by 1 and 5 mg/kg of BCA for 28 days. Body weight and fasting blood glucose were also tested before and at the end of treatment. Furthermore, the size of LDL particles were measured by nondenaturing polyacrylamide gradient gel electrophoresis assay. Results: Results of the present study indicated that BCA administration at dose of 5mg/kg decreased fasting blood glucose level and increased body weight and diameter of LDL particles in diabetic animals significantly. Conclusions: BCA seems to be an appropriate agent in diabetes mellitus, because it improves the diabetic dyslipidemia, which is the most important complication in diabetic patients.

The Insulin Regimen That Works

2018 ◽  
Vol 11 (2) ◽  
pp. 165-168
Author(s):  
Svitlana Crawley ◽  
Susan Chaney
Keyword(s):  
Blood Glucose ◽  
Insulin Therapy ◽  
Nurse Practitioners ◽  
Basal Insulin ◽  
Glycosylated Hemoglobin ◽  
Fasting Blood Glucose ◽  
Diabetic Patients ◽  
Insulin Regimen ◽  
Acting Insulin ◽  
Antihyperglycemic Therapy

Background: Type 2 diabetes mellitus requires monitoring patients’ glycemic control. Treatment must be escalated if glucose levels remain above the recommended goal in patients who are adherent to their current treatment. If glycosylated hemoglobin (HbA1c) levels remain unmet with maximum doses as recommended by the American Diabetes Association (ADA) after adding basal insulin, but fasting blood glucose is at goal, one to three injections daily of rapid-acting insulin are typically added to the treatment plan to be injected prior to meals while continuing all other antihyperglycemic medications. Objective: To describe an effective method of intensifying insulin therapy based on patients’ needs and abilities to self-manage their medications. Methods: We retrospectively reviewed the case of a patient who was referred to the Endocrinology Specialty Clinic for diabetes management. Results: Diabetes control was improved after intensifying insulin therapy by adding once-daily rapid-acting insulin injections. Conclusions: Intensifying insulin therapy by adding one dose of rapid-acting insulin prior to meals can improve HbA1c to < 7% in patients on maximum doses of basal insulin whose fasting blood glucose is at goal but whose HbA1c is above goal. Implications for Nursing: Nurse practitioners must use current care guidelines supported by evidence-based literature to improve patients’ outcomes. This case study supports ADA recommendations on early intensification of antihyperglycemic therapy in diabetic patients to decrease the risk of complications by achieving and maintaining HbA1c goals early.

Sign in / Sign up

Export Citation Format

Share Document